Establishing a Role for Vancomycin Powder Application for Prosthetic Joint Infection Prevention-Results of a Wear Simulation Study Article

Full Text via DOI: 10.1016/j.arth.2014.02.012 PMID: 24636904 Web of Science: 000338941600024

Cited authors

  • Qadir, Rabah; Ochsner, J. Lockwood; Chimento, George F.; Meyer, Mark S.; Waddell, Bradford; Zavatsky, Joseph M.


  • Topical vancomycin powder (VP) has shown efficacy and safety in decreasing post-operative spine infections. VP use in arthroplasty has not been established. Concerns remain for third-body wear with the addition of crystalline substrate at the implant interface. The study's purpose was to compare wear behavior of CoCr on UHMWPE to identical wear couples with VP. A six-station wear simulator was utilized and cyclic articulations were run for 10 million cycles (Mc). UHMWPE wear was measured using photography, stereomicroscopy, and gravimetric measurement. There were no differences in wear mark length (P = 0.43), width (P = 0.49), or gravimetric wear at 10 Mc (P = 0.98). VP and control groups lost 0.32 and 0.33 mg, respectively. VP may have a role in PJI prevention. A well-designed clinical study is needed. (C) 2014 Elsevier Inc. All rights reserved.

Publication date

  • 2014

Published in

International Standard Serial Number (ISSN)

  • 0883-5403

Start page

  • 1449

End page

  • 1456


  • 29


  • 7